Apr 25, 2026
CRISPR Therapeutics (CRSP) Stock Plunges 11% Amid Earnings Disappointment and Competitive Threat
CRISPR Therapeutics (CRSP) stock dropped 11% after missing Q1 estimates badly. Regeneron's free gene therapy approval adds pressure on Casgevy pricing.
The post CRISPR Therapeutics (CRSP) Stock Plunges 11% Amid Earnings Disappointment and Competitive Threat appeared first on Blockonomi.
Source: Blockonomi →Related News
- 15 hours ago
Hewlett Packard Enterprise (HPE) Stock Soars to Record Peak as Elliott Expands P...
- 15 hours ago
Norwegian Cruise Line (NCLH) Stock Plummets 9.5% — Company Insiders Buy Big
- 15 hours ago
Dell (DELL) Stock Rockets 16% to All-Time Peak Ahead of May 28 Earnings
- 15 hours ago
BlackBerry (BB) Stock Surges 19% to New 52-Week Peak on Bullish Outlook
- 15 hours ago
Navitas Semiconductor (NVTS) Stock Soars 20% as AI Power Shift Fuels Rally